Skip to content
Open access

Cancers modulate processing and presentation of p53 neoantigens to evade T cell detection

Sep 2026 · Immunity · Vol 59, pp. 2789 - 2807.e17 · 1 citation · 103 references
Medicine

TL;DR

Findings define mechanisms by which tumors restrict targetable truncal truncal neoantigen display and suggest immunopeptidome shift strategies to circumvent immune escape.

Abstract

SUMMARY TP53 mutations occur early in malignant transformation as truncal events and are therefore generally present in all tumor cells, creating an immunological vulnerability. Here, we examined the immunogenicity and antigenicity of p53 truncal neoantigens. Comprehensive immunopeptidomics revealed that hotspot mutations in human tumors preferentially localize to p53 regions resistant to antigen processing, thereby avoiding display altogether. Moreover, for neoantigens presentable by HLA-A*02:01 or HLA-B*07:02 and structurally divergent from corresponding wild-type p53 peptide-HLA complexes, clinical tumors commonly lacked the relevant presenting HLA allele. Tumor cells further resisted CTL killing through increased ERAP1 activity, preventing display of high-affinity HLA-A*02:01 complexes containing an immunogenic p53I195F-derived 11-mer, or by expressing low-affinity HLA-A*02:01 complexes containing a p53R175H-derived 9-mer with poor antigenicity despite high-quality human TCRs. These findings define mechanisms by which tumors restrict targetable truncal neoantigen display and suggest immunopeptidome shift strategies to circumvent immune escape.

Read PDF

Similar papers

Open access Aug 2026

Structural basis for T-cell receptor recognition of p53Y220D, a human cancer neoantigen.

Adoptive cell therapy (ACT) with tumor-specific T cells can mediate durable cancer regression. The main target of tumor-specific T cells are neoantigens resulting from mutations in self-antigens over the course of malignant transformation. To understand T-cell recognition of cancer neoantigens at the atomic level, we s...

Zhihui Duan, Jian-Feng Zhao, Junping Wu et al. · 0 citations
Review Aug 2026

Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy

Dual immunological identity of mutant p53 (mut-p53) functions as the context-dependent determinant of tumor immunogenicity and cancer immunotherapy outcome, underscoring its promise as both a biomarker and a therapeutic target in crafting next-generation precision cancer immunotherapy strategies.

S. Chakraborty, S. Mukherjee, Subhajit Ghosh et al. · 0 citations
Review Aug 2026

Mechanism of neoantigen generation and advances in neoantigen-based immunotherapies in colorectal cancer

This review outlines the molecular mechanisms driving neoantigen generation in CRC, including frameshift mutations, single-nucleotide variants, alternative RNA splicing, and circular RNA-derived epitopes, and evaluates neoantigen-directed therapeutic platforms, encompassing personalized neoantigen vaccines and adoptive...

Na Wang, Yi-Meng Xia, Ping Wang et al. · 0 citations
#protein folding Sep 2026

Abstract B095: Discovery of treatment-associated peptide antigens for targeted immunotherapies in pancreatic ductal adenocarcinoma

This work provides a framework for identifying actionable treatment-induced peptide antigens and supports rational combination strategies pairing KRAS/RAS inhibitors with T cell-based immunotherapies, including BiTE, CAR-pMHC, TCR-T, and cancer vaccine approaches.

Wei-Xia Kang, Allison Glynn, Harshabad Singh et al. · 0 citations
Review Open access Aug 2026

Targeting splicing-derived neoantigens for precision cancer immunotherapy

This review integrates current understanding of the biological origins, immunological barriers, target classes of splicing neoantigens, and the technologies that enable their advancement in cancer immunotherapy to produce two major classes of immunotherapeutic targets.

Mu-Tian Tang, H. L. Grimes, Nathan Salomonis · 0 citations
Open access Aug 2026

Antigen-directed p53 restoration in TP53-mutated myeloid neoplasms: a hypothesis and theory perspective

TP53-mutated myeloid neoplasms, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), remain among the hardest-to-treat hematologic malignancies, with short survival despite hypomethylating agents +/- venetoclax, and allogeneic transplantation. Despite encouraging early-phase data, Phase 3 trials...

Georgio Medawar, Sadie E. Pyle, P. Baratam et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.